EULAR points to consider for therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal diseases.

EULAR points to consider for therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal diseases – Annals of Rheumatic Diseases

Commentary on Twitter

Our 2022 EULAR points to consider on Therapeutic drug monitoring of biologics just published in @ARD_BMJ

A real pleasure being part of this steering group & collaborative taskforce expertly led by @ProfJohnIsaacs

Clear points for practice& research?https://t.co/YesEjajaIK pic.twitter.com/cQw8o1bjUw

— Meghna Jani (@MeghnaJani) May 15, 2022